China supplies API to dependent Asian markets

Tianjin Pharmacn said there is growing reliance on Chinese APIs.

On the sidelines of API China 2025, Ashikujaman Syed, Sales Manager, International Sales Division at Tianjin Pharmacn Medical Technology, underscored the deepening dependence of Asian pharmaceutical markets on China’s active pharmaceutical ingredients (APIs).

“API China is very important for the pharmaceutical manufacturers, because for Southeast Asia, we need lots of API from China,” he said, noting that communication gaps remain a key challenge.

Syed highlighted that markets like Bangladesh remain fully reliant on Chinese API suppliers. “We don't produce API, but we are totally dependent on China,” he said, adding that domestic production may only begin after 2030, when new competition could emerge.